You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

~ Buy the XPOVIO (selinexor) Drug Profile, 2024 PDF Report in the Report Store ~

XPOVIO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xpovio, and what generic alternatives are available?

Xpovio is a drug marketed by Karyopharm Theraps and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and twenty-seven patent family members in thirty-eight countries.

The generic ingredient in XPOVIO is selinexor. One supplier is listed for this compound. Additional details are available on the selinexor profile page.

DrugPatentWatch® Generic Entry Outlook for Xpovio

Xpovio was eligible for patent challenges on July 3, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 14, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for XPOVIO?
  • What are the global sales for XPOVIO?
  • What is Average Wholesale Price for XPOVIO?
Summary for XPOVIO
International Patents:127
US Patents:10
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 47
Clinical Trials: 24
Patent Applications: 134
Drug Prices: Drug price information for XPOVIO
What excipients (inactive ingredients) are in XPOVIO?XPOVIO excipients list
DailyMed Link:XPOVIO at DailyMed
Drug patent expirations by year for XPOVIO
Drug Prices for XPOVIO

See drug prices for XPOVIO

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XPOVIO
Generic Entry Date for XPOVIO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XPOVIO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MiamiPhase 2
Xia ZhongjunPhase 1/Phase 2
Li ZhimingPhase 2

See all XPOVIO clinical trials

US Patents and Regulatory Information for XPOVIO

XPOVIO is protected by twenty-two US patents and seven FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XPOVIO is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XPOVIO

Polymorphs of Selinexor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES

Polymorphs of Selinexor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY

Polymorphs of Selinexor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

Hydrazide containing nuclear transport modulators and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting XPOVIO

IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
Exclusivity Expiration: ⤷  Sign Up

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
Exclusivity Expiration: ⤷  Sign Up

FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, EXCLUDING ADULT PATIENTS COVERED BY XPOVIO'S PREVIOUS INDICATION FOR MULTIPLE MYELOMA APPROVED ON JULY 3, 2019
Exclusivity Expiration: ⤷  Sign Up

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Sign Up

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Sign Up

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-004 Apr 15, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for XPOVIO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Stemline Therapeutics B.V. Nexpovio selinexor EMEA/H/C/005127
NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Authorised no no no 2021-03-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for XPOVIO

When does loss-of-exclusivity occur for XPOVIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15301484
Patent: Polymorphs of selinexor
Estimated Expiration: ⤷  Sign Up

Patent: 20203246
Patent: Polymorphs of selinexor
Estimated Expiration: ⤷  Sign Up

Patent: 21286266
Patent: Polymorphs of selinexor
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 57266
Patent: FORMES POLYMORPHES DE SELINEXOR (POLYMORPHS OF SELINEXOR)
Estimated Expiration: ⤷  Sign Up

China

Patent: 7072992
Patent: 赛灵克斯的多晶型物 (Polymorphs of selinexor)
Estimated Expiration: ⤷  Sign Up

Patent: 1481553
Patent: 赛灵克斯的多晶型物 (Polymorphs of selinexor)
Estimated Expiration: ⤷  Sign Up

Patent: 1484483
Patent: 赛灵克斯的多晶型物 (Polymorphs of selinexor)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 17001884
Patent: Polimorfos de selinexor
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 80331
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1790384
Patent: ПОЛИМОРФЫ СЕЛИНЕКСОРА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 80331
Patent: FORMES POLYMORPHES DE SELINEXOR (POLYMORPHS OF SELINEXOR)
Estimated Expiration: ⤷  Sign Up

Patent: 12615
Patent: COMPOSITIONS COMPRENANT UNE FORME CRISTALLINE DE SELINEXOR (COMPOSITIONS COMPRISING ONE CRYSTALLINE FORM OF SELINEXOR)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 0328
Patent: פולימורפים של סלינקסור (Polymorphs of selinexor)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 77626
Estimated Expiration: ⤷  Sign Up

Patent: 18323
Estimated Expiration: ⤷  Sign Up

Patent: 17527549
Patent: セリネクソールの多形体
Estimated Expiration: ⤷  Sign Up

Patent: 20143144
Patent: セリネクソールの多形体 (POLYMORPHS OF SELINEXOR)
Estimated Expiration: ⤷  Sign Up

Patent: 23052622
Patent: セリネクソールの多形体
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 17002013
Patent: POLIMORFOS DE SELINEXOR. (POLYMORPHS OF SELINEXOR.)
Estimated Expiration: ⤷  Sign Up

Patent: 21014128
Patent: POLIMORFOS DE SELINEXOR. (POLYMORPHS OF SELINEXOR.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 254
Patent: POLYMORPHES DU SELINEXOR
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 8850
Patent: Polymorphs of selinexor
Estimated Expiration: ⤷  Sign Up

Patent: 7083
Patent: Polymorphs of selinexor
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201808624V
Patent: POLYMORPHS OF SELINEXOR
Estimated Expiration: ⤷  Sign Up

Patent: 201700789S
Patent: POLYMORPHS OF SELINEXOR
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1700880
Patent: POLYMORPHS OF SELINEXOR
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2608259
Estimated Expiration: ⤷  Sign Up

Patent: 170043561
Patent: 셀리넥소의 다형태 (POLYMORPHS OF SELINEXOR)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 26377
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 3535
Patent: ПОЛІМОРФИ СЕЛІНЕКСОРУ (POLYMORPHS OF SELINEXOR)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XPOVIO around the world.

Country Patent Number Title Estimated Expiration
China 103842340 Nuclear transport modulators and uses thereof ⤷  Sign Up
Denmark 2736887 ⤷  Sign Up
Lithuania PA2021007 ⤷  Sign Up
South Korea 102022716 ⤷  Sign Up
European Patent Office 3180331 FORMES POLYMORPHES DE SELINEXOR (POLYMORPHS OF SELINEXOR) ⤷  Sign Up
Hong Kong 1256745 含酰肼的核運輸調節劑及其用途 (HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XPOVIO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2736887 2190030-3 Sweden ⤷  Sign Up PRODUCT NAME: SELINEXOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1537 20210329
2736887 LUC00219 Luxembourg ⤷  Sign Up PRODUCT NAME: SELINEXOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1537 20210329
2736887 21C1042 France ⤷  Sign Up PRODUCT NAME: SELINEXOR OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/21/1537 20210329; FIRST REGISTRATION: FR - EU/1/21/1537 20210329
2736887 2021033 Norway ⤷  Sign Up PRODUCT NAME: SELINEKSOR ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/21/1537 20210408
2736887 PA2021007,C2736887 Lithuania ⤷  Sign Up PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326
2736887 PA2021007 Lithuania ⤷  Sign Up PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.